11.30.22 -- CDMO Performance

Review three biopharma contract manufacturing trends that are indicators of exciting industry developments and also reveal areas that are ripe for change.

It is important to adopt strategies that create simple but stable formulations for your sterile injectable, thereby establishing a solid foundation for the entire life cycle of your product.

This article captures learnings about the use of single-use technologies in biopharma manufacturing that can be applied to cell and gene therapies, with a special focus on connection technologies.

An increasing number of poorly soluble active pharmaceutical ingredients (APIs) are the cornerstone of cutting-edge therapies, necessitating equally complex formulation technologies to maintain or improve solubility and, ultimately, bioavailability.

While most oral solid formulations are designed to release the drug immediately after swallowing, some products have been developed to provide a “controlled-release” of the drug products.

The microbes residing in our gastrointestinal tracts, or the “gut microbiome,” are essential contributors to metabolism and may hold the promise of new treatments for a range of therapeutic applications.

Standardized approaches to biomanufacturing can lower costs, improve outcomes, and alter the landscape of the global pharmaceutical market.

Growing complexity and risks in drug development and supply have implications for outsourcing models. See how to structure and manage CDMO partnerships for a future full of uncertainty and disruption.

Innovative softgel technologies that maximize your market potential: Where ideation and expertise come together.

Learn more about a way to streamline the downstream process using variable pathlength technology to determine the DBC of affinity chromatography resins to produce reliable data more effectively and efficiently.

Dr. Claudia Müller answers questions from a webinar about the complex path to a successful product launch, which requires a holistic development strategy driven by a well-defined target product profile.

Explore flexible solutions that enable you to seamlessly guide your molecule through each early development phase with efficiency and speed.

The pros and cons of soluble and insoluble processes: isolating, solubilizing, and properly refolding, and strategies to improve the performance of IB processes.

The journey of a novel bioconjugate into the clinic is complex and uncertain. Explore the particular challenges when moving a bioconjugate candidate from early development into the clinic.

Review key considerations for formulation screening of therapeutic proteins and how consistency, planning, and communication are essential for a successful biologic drug product tech transfer.

The successful outcomes delivered by cell and gene therapies, coupled with the emergence of modalities across nucleic acid therapeutics and microbiomes, pose the next scalability challenges.